Johnson & Johnson CEO Gorsky Reaffirms Diversified Strategy
This article was originally published in The Gray Sheet
Executive Summary
Faced with spin-off models from other diversified health care firms, including Abbott and Pfizer, Gorsky defended J&J’s broader-based approach as a better long-term strategy.
You may also be interested in...
People In Brief
Gorsky assumes chairmanship at J&J. John Yonkin named CEO at Immunetics. More news on people in the device and diagnostics industries.
Biomet Cites Q4 Sales Boost From JuggerKnot Sports Med Implants
The company’s sports, extremities and trauma products generated 14% growth last quarter with the help of its JuggerKnot Soft Anchor sports medicine products.
J&J Eyes Restructured Device Biz As New CEO Gorsky Steps In
Big changes are underway at J&J. In April, Alex Gorsky will become the company’s new CEO. And the firm plans a restructuring of its device business upon completion of its $20 billion-plus Synthes acquisition in the first half of the year.